Now Is the Time for Detransition Diagnosis Codes

Key Takeaways

• CDC accepted remission code for Oct 2026 implementation
• Revised proposal seeks three codes for transition phases
• Public comment period ends April 17, 2026
• Codes will enable billing, data collection, research
• Visibility will improve care for detransitioning patients

Summary

Dr. Kurt Miceli of Do No Harm urged the creation of specific ICD‑10‑CM diagnosis codes for detransition at the Detrans Awareness Day conference. The CDC’s ICD‑10 Coordination and Maintenance Committee has approved a remission code, F64.A, slated for October 2026, and a revised proposal now seeks three additional codes covering social, medical and surgical transition phases as well as detransition. The proposal is in a 30‑day public comment window ending April 17, 2026. If adopted, these codes would standardize documentation, billing and research on gender‑identity care.

Pulse Analysis

The International Classification of Diseases, 10th Revision, Clinical Modification (ICD‑10‑CM) underpins every claim, quality metric and epidemiological study in the United States. Yet, despite its 70,000‑plus entries, the system lacks a code that captures the clinical reality of detransition—a gap that leaves providers without a standardized way to document care and insurers without clear billing pathways. This omission also skews health‑services research, as data on post‑transition outcomes remain fragmented and invisible.

In March 2026, the CDC’s ICD‑10 Coordination and Maintenance Committee approved a new code, F64.A Gender identity disorder, in remission, for implementation on October 1, 2026. Building on three years of groundwork by physicians such as Drs. Carrie Mendoza and Aida Cerundolo, Do No Harm has submitted a revised proposal that adds three distinct codes to differentiate social, pharmacological and surgical transition states, plus a dedicated detransition code. The proposal is currently open for public comment until April 17, inviting clinicians, advocacy groups and researchers to shape the final language.

Adopting these codes would have immediate operational benefits: clinicians could accurately record patient encounters, insurers could process claims without ambiguity, and health systems could generate reliable datasets on transition‑related complications. Over the longer term, granular coding will enable robust outcome studies, inform evidence‑based guidelines, and guide policymakers on resource allocation for gender‑affirming and detransition services. The momentum around these codes signals a broader shift toward inclusive, data‑driven care for all gender‑diverse patients.